The role of Prostate Imaging Reporting and Data System score in Gleason 3 + 3 active surveillance candidates enrollment: a diagnostic meta-analysis
- PMID: 30429594
- DOI: 10.1038/s41391-018-0111-4
The role of Prostate Imaging Reporting and Data System score in Gleason 3 + 3 active surveillance candidates enrollment: a diagnostic meta-analysis
Abstract
Background: The contemporary active surveillance (AS) criteria may result in an unsatisfactory misclassification rate, which may delay curative treatment for prostate cancer patients. The magnetic resonance imaging (MRI), not included in any AS criteria, provides useful information for prostate cancer diagnosis. Our goal is to evaluate the diagnostic performance of Prostate Imaging Reporting and Data Systems (PI-RADS) score, a standardized MRI reporting system, in AS candidates enrollment.
Methods: We searched Cochrane CENTRAL, PubMed, and Embase for pertinent studies through June 2018. The standard methods recommended for meta-analyses of diagnostic evaluation were employed. We draw the summary receiver operating characteristic (SROC) curve. Meta-regression analysis was performed to evaluate the effects of confounding factors.
Results: From the resulting 168 studies, 5 provided the diagnostic data on PI-RADS score and pathological results; 834 patients were included. All AS candidates in these studies were defined by Prostate Cancer Research International: Active Surveillance (PRIAS) criterion. The pooled estimates of PI-RADS 4 or 5 on adverse pathological features at radical prostatectomy (RP) among AS candidates were: sensitivity, 0.77 (95% confidence interval (CI), 0.71-0.82); specificity, 0.63 (95% CI, 0.55-0.71); positive predictive value, 0.72 (95% CI, 0.64-0.79); negative predictive value, 0.68 (95% CI, 0.63-0.73); and diagnostic odds ratio, 6 (95% CI, 4-8). The SROC curve was positioned toward the desired upper left corner of the curve, the area under the curve was 0.77 (95% CI, 0.73-0.80). The P-value for heterogeneity was <0.01. The pathological outcomes and endorectal coils contributed to the heterogeneity of sensitivity. The evidences supporting the advantage of PI-RADS v2 over v1 were not sufficient yet.
Conclusion: AS candidates with PI-RADS 4 or 5 may be unsuitable for AS even though they fulfill current AS criteria. Those with PI-RADS 3 or less indicated relative safety for AS enrollment.
Similar articles
-
Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis.Prostate Cancer Prostatic Dis. 2015 Sep;18(3):221-8. doi: 10.1038/pcan.2015.20. Epub 2015 May 19. Prostate Cancer Prostatic Dis. 2015. PMID: 25986915 Review.
-
Comparison of diagnostic performance between two prostate imaging reporting and data system versions: A systematic review.Eur J Radiol. 2019 May;114:111-119. doi: 10.1016/j.ejrad.2019.03.016. Epub 2019 Mar 20. Eur J Radiol. 2019. PMID: 31005160
-
Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.Urol Int. 2018;101(1):56-64. doi: 10.1159/000488772. Epub 2018 May 7. Urol Int. 2018. PMID: 29734177
-
Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.J Magn Reson Imaging. 2018 Apr;47(4):1072-1079. doi: 10.1002/jmri.25856. Epub 2017 Sep 13. J Magn Reson Imaging. 2018. PMID: 28901655
-
Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.Urology. 2018 Jun;116:137-143. doi: 10.1016/j.urology.2018.02.043. Epub 2018 Apr 10. Urology. 2018. PMID: 29653121
Cited by
-
Complementing the active surveillance criteria with multiparametric magnetic resonance imaging.Investig Clin Urol. 2020 Nov;61(6):573-581. doi: 10.4111/icu.20200159. Investig Clin Urol. 2020. PMID: 33135402 Free PMC article.
-
MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance.Sci Rep. 2021 Jun 21;11(1):12917. doi: 10.1038/s41598-021-92341-6. Sci Rep. 2021. PMID: 34155265 Free PMC article.
-
The current role of MRI for guiding active surveillance in prostate cancer.Nat Rev Urol. 2022 Jun;19(6):357-365. doi: 10.1038/s41585-022-00587-0. Epub 2022 Apr 7. Nat Rev Urol. 2022. PMID: 35393568 Review.
-
Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.Eur Urol. 2020 Sep;78(3):443-451. doi: 10.1016/j.eururo.2020.03.035. Epub 2020 Apr 30. Eur Urol. 2020. PMID: 32360049 Free PMC article.
-
Diagnostic Accuracy of Contemporary Selection Criteria in Prostate Cancer Patients Eligible for Active Surveillance: A Bayesian Network Meta-Analysis.Front Oncol. 2022 Jan 10;11:810736. doi: 10.3389/fonc.2021.810736. eCollection 2021. Front Oncol. 2022. PMID: 35083157 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous